ArticleAIDS and behavior2025
"I Just Stopped Taking PrEP Without a Reason": Understanding PrEP Decision-Making Amongst South African Adolescent Girls and Young Women (AGYW).
Article in AIDS and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Pre-exposure prophylaxis (PrEP) use is not a once-off bio-behavioural strategy but part of ongoing HIV prevention decision-making. We explored PrEP decision-making through qualitative interviews with 68 adolescent girls and young women (AGYW) aged 15-24 years from communities in which a large-scale combination prevention intervention supporting daily oral PrEP uptake for AGYW in South Africa was implemented. Thematic analysis of transcripts was informed by a social-ecological framework. AGYW's decisions to initiate, continue, discontinue, or refuse PrEP were shaped by intersecting individual, interpersonal, health system, and contextual factors. At the individual level, self-motivation for HIV protection and distrust of partners supported initiation and continuation, reinforced by regular HIV-negative results, while side effects, dislike of daily pills, and perceived contraindications drove discontinuation. Decisions to refuse PrEP centred around low perceived HIV risk, fear of side effects, and aversion to daily tablets, although many expressed conditional interest in future long-acting formulations. Interpersonally, disclosure to and encouragement from family, partners, or friends enabled continuation, whereas inability to disclose, limited social support, and relationship changes undermined adherence. At the health system level, provider engagement, support, and perceived confidentiality of services and packaging were pivotal. Contextually, PrEP-related stigma constrained use, while living in high HIV-prevalence, unsafe communities heightened risk perception and encouraged uptake. PrEP use among AGYW is dynamic and temporal, shaped by relationships, communication and disclosure, embodied experiences, stigma, and service experiences. There is a need for tailored, responsive prevention counselling and service delivery to support AGYW's PrEP initiation, persistence, and informed decisions about sexual health.
Indexed as
Identifiers
41422441What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.